Charcot Marie Tooth Disorders

Published Date : Feb 2024
Category : Neurodegenerative Disorders
Delivery Timeline : 48 hrs
Buy NowOrder by POGet a quote
Login To Access

“Addressing the Challenges and Prospects of Charcot Marie Tooth Disorders”

One of the most prevalent hereditary neurological conditions, CMT has several variants that vary in severity. The worldwide impact of the disease goes beyond the psychological and physical toll it takes on an individual; it also includes healthcare expenses, societal ramifications, and the possible financial burden of long-term care and rehabilitation. Because Charcot-Marie-Tooth disease is so common that it affects people everywhere, research, healthcare systems, and public awareness campaigns must work together to improve the condition's diagnosis, treatment, and support for those who are impacted by this difficult neurological disorder.

According to the National Institute of Health the incidence of CMT is 1 in every 2500 persons, CMTs collectively represent the most prevalent hereditary neuromuscular condition.

However, the prevalence of the cmt neurological disease is varying with different countries for instance, prevalence range in Serbia 9.7 per 100,000 persons on the other hand in Norway it is 82.3 per 100,000 in Norway. The mostly causing type of a CMT is CMT1A which have affected 150000 people all over Europe and United states. CMT1A have affected 15,00,000 persons across the world. Estimates of prevalence in recent times range from 9 to 28 per 100,000. Also, mortality ratio of CMT is about 1.57%. Charcot Marie Tooth Diseases is basically caused by genetic mutations which affects the body peripheral nerves which led in further weakness of body. The 70-80% of CMT case causes due to the duplication of large region chromosome 17 which includes the PMP22 gene. Diagnosis of the CMT basically done by three types by measuring speed nerve impulse, biopsy of nerve and by DNA testing.

The treatment field of the CMT neurological disorder is continuously growing and working on new drug developments for better cure of the CMT. For instance, the experimental medication DTx-1252 from DTx Pharma was recently recognized as an orphan medicine by the US Food and Drug Administration (FDA) to treat Charcot-Marie-Tooth diseases Type 1A (CMT1A). The approval for various drugs is the driver for the market growth of Charcot Marie Tooth Diseases (CMT).

The Charcot Marie Tooth Diseases (CMT) is divided into five types CMT1 (CMT1A, CMT1B), CMT2, CMT3, CMT4, CMTX1.

Myelin sheath irregularities are the main root cause of CMT1. The disease is further classified in two subtypes CMT1A and CMT1B. According to reports of National Institute of Health, CMT1 accounts for between 37.6% and 84.0% of cases, making it the most prevalent type of disease. CMT2, CMT3, CMT4 and CMTX1 are less prevalent diseases as compared to the CMT1 disease.

 The above disease is caused by mutations in the peripheral nerve cell's axon.

Charcot Marie tooth syndrome symptoms and signs

The cmt disease symptoms are as follows:

  • Decrease in the vibration and position senses.
  • Trouble in balancing body
  • Pain in nerves
  • Muscle cramping
  • Displacements in hip
  • Curve in the spine
  • Difficulties in motor skills

Diagnostic Analysis

The Charcot Marie Tooth Diseases are quite easy to diagnose since all individuals exhibit the same symptoms. The following are the main diagnostic categories, which have a significant influence on the market depending on many factors such the advancement of diagnostic technology. The most popular methods for diagnosing c marie tooth diseases are listed below.

  • Electromyogram Testing
  • Genetic Testing
  • Ultrasound Testing
  • Nerve Biopsy
  • Magnetic Resonance Imaging (mri)
  • Spinal Tap (lumbar puncture)

Electromyogram Testing

Electromyography (EMG) measures the electrical activity of muscles by inserting a tiny, needle-shaped electrode into the skin. An EMG reveals a specific variation in the electrical activity pattern caused by some kinds of cmt marie tooth. Electromyogram is able to detect the CMT with 94.5% accuracy. Because of the accuracy in the detection this device is mostly used as it became the one driving factor for the charcot marie tooth cmt disease Market growth.

Genetic Testing

Using a blood sample, genetic testing looks for faulty genes that are known to cause CMT. The majority of CMT patients able to determine their exact form of charcot marie tooth cmt disorder and have their diagnosis examined by genetic testing. Basically the variations in the PMP22 gene are detected in the genetic testing.

Ultrasound Testing

The test measures the thickness of the media and intima, the inner two layers of the carotid artery, using high-frequency sound waves, and informs physicians of any thickening while patients are still unnoticed. The test is carried out by putting a gel on the neck's skin and sending and receiving sound waves that reflect off the carotid arteries using a device called a transducer.

Nerve Biopsy

In a rare number of situations when previous testing provided inconsistent outcomes, a nerve biopsy test is sometimes performed. This is a minimally invasive surgical technique where a peripheral nerve sample is taken from the leg for examination purposes. Under a microscope, cmt charcot results in physical abnormalities to the nerve's appearance. The whole process is done under the under local anesthesia.

Top Players of Diagnostic Kits

The global market for CMT testing is very competitive, which implies that several significant players in the field have a global presence. Included in the list below are the top manufacturers of CMT diagnostic kits.

Diagnostic Market Player

Diagnostic Product

Allengers Global Healthcare Pvt limited.


Cadwell Industries

Sierra Summit®

Cometa System Inc.

Pico EMG

EMS Biomedical


EB Neuro

NeMus 1

Tought technology

EMG MyoScan™

Nihon Kohden

Neuropack® S3


UltraPro® S100

Contech Instruments Ltd.

Nicolet EDX® EMG

Shimmer Wearable Sensor Technology



Shimmer3 EMG


Ultium™ EMG


Trigno Galileo Sensor



OT Bioelettronica





Treatment Analysis

Basically there is no cure for the Charcot Marie Tooth Diseases. This field of charcot marie tooth disease treatment is constantly growing and exploring new drugs to improve cure for cmt. For example, the US Food and Drug Administration (FDA) has designated the investigational drug DTx-1252 from DTx Pharma as an orphan medicine to treat Charcot-Marie-Tooth disorders Type 1A (CMT1A).

Furthermore the leading key player in the treatment of Charcot Marie Tooth Diseases Novartis on Jul 17, 2023 has signed deal with DTx Pharma which basically works on the further treatment advancements on Charcot Marie Tooth Diseases. Various types of medication treatment and therapies are used in the Charcot Marie Tooth Diseases. Some of the mostly used cmt disease treatment therapies are listed below. 

  • Physical therapy
  • Occupational therapy
  • Orthopedic devices

Physical Therapy

One of the most effective treatments treating CMT symptoms and minimizing the chance of muscular contractures a condition in which muscles shorten and lose their normal range of motion is physiotherapy. Physiotherapy promotes wellness and rehabilitation through the use of physical techniques manipulation and massage.

Occupational Therapy

In occupational therapy, identify elements of the daily life, clothing themselves, that are problematic and then come up with viable solutions. Occupational therapy helpful if patient has trouble doing regular tasks for instance writing or dressing due to muscular weakness in hands and arms. Using assistive technology, such rubber grips on doorknobs or button-free clothes, beneficial when occupational therapy is used.

Orthopedic Devices

Orthopedic devices are necessary for many people with Charcot disease to preserve daily movement and prevent harm. Stabilizing support while walking and stair climbing achieved with leg and ankle braces or splints. The orthopedic devices are one of the drivers for the further growth of the Charcot-Marie-Tooth disease market.

  • Outhouses come in a variety of forms, including:
  • Specially created ankle-supporting insoles for shoes
  • Ankle or limb braces

Treatment Market Player

Some of the major key players of Charcot-Marie-Tooth disease market are listed below

Sr No

Treatment Market Player

Treatment Product





Alex Orthopedic

Ankle Support



Bio Skin



Polar ice


DARCO Medical India Pvt. Ltd.

DARCO Web Ankle Brace



Stabilizing Pro Ankle Brace


Osteoplast Wellness Private Limited






Antara Senior Care




Tynor Ankle Brace



NEENCA Professional Ankle Brace



DonJoy Ankle Braces


Competition Analysis

  • The market for Charcot-Marie-Tooth disease is fragmented, with a few major firms controlling a large portion of it. Key market participants have used several tactics, including as strategic partnerships and collaborations, product innovation and development, mergers and acquisitions, and growth into new markets, in order to remain competitive.
  • Strategic partnerships and collaborations have also been key strategy for key market players, as it allows them to expand their product portfolio and enter new markets. For instance on March 10, 2021 the Bioskin announced the strategic partnership with the Viedoc Technologies.
  • Mergers and acquisitions have also been a common strategy in the Charcot-Marie-Tooth disease market, as it allows key market players to expand their market share and product portfolio. For example the on Feb. 1 2021 Cadwell Industries, Inc. completes the acquisition of the
  • Finally, key market players have also focused on expanding into emerging markets, such as Asia-Pacific and Latin America, to tap into the growing demand.

Market Trends Analysis

Technological advancement in treatment of CMT

The Charcot-Marie-Tooth (CMT) disease research team, under the direction of Professor Minseok Kim of the Department of New Biology at DGIST (President Yang Kuk), has created a method that uses electric stimulation rather than medication therapy to cure the genetic condition, which is incurable. This technique holds great promise for the creation of an electronic medication with few adverse effects in the future.

This technology's main component, electric stimulation, corrects the disease-causing aberrant distribution of peripheral myelin protein 22 (PMP 22). The discovery was made by the study team utilizing a CMT disease subtype 1A (CMT1A) cell model in a series of electric stimulation studies.

Clinical Assessment

Building up and carrying out clinical trials for novel medications and cures, patient recruitment tactics, regulatory compliance, ensuring effective trial outcomes, etc., is all made easier with the support of DiseaseLandscape Insights. The study titles of the current clinical trials around Charcot-Marie-Tooth (CMT) are included in the table below, along with the phase in which they are now being done.

Phase 1

Phase 2

Phase 3

Phase 4

A Phase 1, Open-Label, Prospective, Dose-finding Clinical Trial for Evaluation of Safety and Tolerability of Intramuscular Injections of CLZ-2002 for the Treatment of Subjects with Charcot-Marie-Tooth Type 1(CMT 1)

Phase 2 Clinical Trial of FIsetin to Treat CArpal Tunnel Syndrome (FITCATS)

A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Phase III Study to Assess the Efficacy and Safety of PXT3003 in Charcot-Marie-Tooth Type 1A (CMT1A) Treated 15 Months

The Therapeutic Effect and Quality of Life After Local Injection of Steroid VS. Glucose 5% for Carpal Tunnel Syndrome : Double-blinded Clinical Trial

Conditioning Electrical Stimulation to Improve Outcomes in Carpal Tunnel Syndrome

Conditioning Electrical Stimulation to Improve Outcomes in Carpal Tunnel Syndrome

Comparison of the Efficacy Between Ultrasound-guided Dextrose Injection Versus Dextrose With Methylprednisolone Injection in Patients With Carpal Tunnel Syndrome: a Prospective, Randomized Double-blind Clinical Trial.

The NOR-CACTUS Trial - A Norwegian Trial Comparing Treatment Strategies for Carpal Tunnel Syndrome

A Randomized, Double-Blind, Placebo-Controlled, First-in-Human, Single and Multiple Ascending Dose Study of MTR-601 in Healthy Volunteers.

BotulInum Toxin Type A for Peripheral Neuropathic Pain in subjEcts With Carpal Tunnel Syndrome: a Multicenter, Randomized, Doubleblind, Placebo-controlled Study

The Soft Tissue Injection of Corticosteroid And Local Anaesthetic Study - A Single Site, Non-inferiority Randomised Control Trial Evaluating Pain After Soft Tissue Corticosteroid Injections With and Without Local Anaesthetic

Exparel and Education to Avoid Opioids After Carpal Tunnel Release


MT2013-31: Allogeneic Hematopoietic Cell Transplantation for Inherited Metabolic Disorders and Severe Osteopetrosis Following Conditioning With Busulfan (Therapeutic Drug Monitoring), Fludarabine +/- ATG





The market for Charcot Marie Tooth syndrome has certain challenges, but DiseaseLandscape Insights assists by providing industry players with answers to these challenges. DiseasesLandscape Insights offers carefully selected, informative information to the healthcare industry.

Disease Landscape Insights will provide significant services for the business segment. Setting up and running clinical trials for novel drugs and treatments, as well as for patient recruiting tactics, regulatory compliance, guaranteeing successful trial outcomes, etc., is made simpler with the assistance provided by Disease Landscape Insights. 

DLI services are the engine that drives successful drug launches with favorable outcomes. Beyond providing data on treatment trends and disease incidence, DiseaseLandscape Insights Services offers a wide range of services.

Vishal SawantBusiness Development

How we can help?

  • 1-888-853-7040 - U.S. (TOLL FREE)
  • +44-1173181773 - U.K. OFFICE
  • +91-7447409162 - INDIA OFFICE
1Chat With UsBook AppointmentBook 15 min Free Analyst Call
We are always looking to hire talented individuals with equal and extraordinary proportions of industry expertise, problem solving ability and inclination interested? please email us
  • FAQ
Disease Landscape Insights LLP
6th Floor, Sr No.207, Office A H 6070 Phase 1, Solitaire Business Hub, Viman Nagar, Pune, Maharashtra, 411014
1-888-853-7040 - U.S. (TOLL FREE)+44-1173181773 - U.K. OFFICE+91-7447409162 - INDIA OFFICE
© Copyright 2024-25 Disease Landscape Insights LLP. All Rights Reserved | Designed by Disease Landscape